---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-016652"
form_type: "8-K"
ticker: "VTGN"
cik: "0001411685"
company_name: "Vistagen Therapeutics, Inc."
filed_at: "2026-03-11T23:59:59+00:00"
generated_at: "2026-05-15T14:44:44.586224+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Vistagen cuts workforce 20%, cites cash management; PALISADE-4 results expected H1 2026

## Summary
- Reduced workforce by approximately 20% to prioritize fasedienol PALISADE-4 Phase 3 trial.
- Topline results from PALISADE-4 for social anxiety disorder expected first half of 2026.
- Company expects cash runway to extend into 2027 after the workforce reduction.
- Affected employees may receive cash severance and healthcare coverage; costs expected immaterial.

## SEC filing metadata
- accession: 0001628280-26-016652
- form_type: 8-K
- ticker: VTGN
- cik: 0001411685
- company_name: Vistagen Therapeutics, Inc.
- filed_at: 2026-03-11T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1411685/000162828026016652/0001628280-26-016652-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1411685/000162828026016652/vtgn-20260305.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-016652
- JSON: https://secwatch.observer/filing/0001628280-26-016652.json
- Plain text: https://secwatch.observer/filing/0001628280-26-016652.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.